Kornimate/medical-research-clean huggingface dataset:
effects of oxytocin and carbetocin on renal system in cesarean sections

Conditions: Postpartum Hemorrhage

Summary: the aim of this study is to evaluate the renal outcome of patients undergoing elective c/s where oxytocin or carbetocin is used for postpartum hemorrhage prophylaxis.


Eligibility criteria:
inclusion criteria: * term (\>37 weeks of gestation) uncomplicated pregnant women undergoing elective cesarean section exclusion criteria: * patients refusing to participate in the study * complicated pregnancies * patients with risk factors for postpartum hemorrhage * contraindications for oxytocin or carbetocin usage * patients with known renal diseases * preterm births (\<37 weeks of gestation)
determination of cell population in solution-induced corneal staining (sics) and symptomatic versus asymptomatic lens wearers

Conditions: Refractive Error; Dry Eye

Summary: the purpose of the study is to investigate the corneal epithelial cell response associated with lens wear that results in solution-induced corneal staining (phase1) and to determine the cell appearance in symptomatic and asymptomatic contact lens wearers (phase 2).

this study consisted of 2 phases. in phase 1, participants wore contact lenses pre-soaked overnight in contact lens solution for 2 hours and 4 hours, separate days. a minimum of 7 days separated the wear periods. ocular surface cells were collected after both wear periods. in phase 2, participants wore their habitual contact lenses on a daily wear basis for 4 weeks with habitual lens care. ocular surface cells were collected after day 1 and day 28. phase 2 included eligible participants who completed phase 1 and new participants. a participant was considered to be asymptomatic if he/she can typically wear contact lenses comfortably for at least 10 hours/day a minimum of 5 days/week, and symptomatic if he/she typically wears contact lenses for a minimum of 3 days/week and experiences ocular discomfort after less than 6 hours of wear. phase 1 participants not eligible to participate in phase 2 or uninterested in continuing into phase 2 were exited from the study.

Eligibility criteria:
inclusion criteria (phase 1): * full legal capacity to volunteer. * read and sign an informed consent form. * willing and able to follow instructions and maintain the appointment schedule. * current or previous contact lens wearer and competent to insert and remove contact lenses. * up-to-date spectacles. * other protocol-defined inclusion criteria may apply. inclusion criteria (phase 2): * full legal capacity to volunteer. * read and sign an informed consent form. * willing and able to follow instructions and maintain the appointment schedule. * up-to-date spectacles. * wears single vision silicone hydrogel contact lenses, following a monthly replacement schedule. * has worn the same lens type for a minimum of 2 months, with the exception of the 2 periods of lens wear for participants who were also in phase 1. * has used the same type of cleaning solution for a minimum of 2 months. * currently wears brand name contact lenses and uses brand name cleaning solutions that are commercially available in canada (no private labels). * other protocol-defined inclusion criteria may apply. exclusion criteria (phase 1 and 2): * any ocular disease. * systemic condition that may affect a study outcome variable. * use of any systemic or topical medications that may affect ocular health. * known sensitivity to the diagnostic pharmaceuticals to be used in the study. * presents with significant amounts of corneal staining. * current use of artificial tears and/or rewetting drops. * wears contact lenses on an extended (overnight) or continuous wear schedule. * other protocol-defined exclusion criteria may apply.
healthcare worker exposure response and outcomes (hero) registry study, covid-19

Conditions: Health Care Worker (HCW); COVID-19

Summary: the hero registry provides a resource for collecting information on healthcare workers (hcws) currently working in the united states, and their families and communities. the overall goal of the registry is to develop the infrastructure necessary to create and engage a community of people who may be eligible for participation in future research studies, including those of covid-19 prophylaxis and treatment.

the hero registry provides a resource for collecting information on healthcare workers (hcws) currently working in the united states, and their family members and communities. the overall goal of the registry is to create and engage a community of hcws and their families and communities who may be eligible for participation in future research studies, including those of covid-19 prophylaxis and treatment. the hero registry will create a repository of adults interested in covid-19 research that can be eligible for future research studies. the main objectives of the study are 1) create a virtual community of adult hcws in the united states, and their families and communities, 2) identify adults interested in engaging in upcoming research studies, including those related to covid-19, and 3) create a dataset of health related measurements, risk factors, and outcomes for future analysis. the population of interest is adult healthcare workers in the united states, and their families and communities. all analysis of the hero registry will be exploratory in nature. analysis may include descriptive statistics of the cohort, statistical associations between variables of interest, and predictive modeling for health outcomes and behaviors. analyses may be conducted on all participants in the hero registry or may be conducted on subpopulations defined based on clinical, demographic or other factors. there is no direct benefit to the participants for their participation in this study, but the information obtained will be used in scientific research and may be helpful to the participant or others in the future. participants may experience indirect benefits such as learning about their own health, access to health data, and opportunities to participate in future research.

Eligibility criteria:
inclusion criteria: * a member of one of the following three groups: * individual currently works in a setting where individuals receive healthcare ("healthcare worker") (including emergency medical services), or * a family member of a healthcare worker, or * a member of a healthcare worker's community * age ≥ 18 * able to speak and read english or spanish exclusion criteria: \* there are no specific exclusion criteria for this study. participants must meet inclusion criteria.
diagnosis and outcomes of placental accretism

Conditions: Placenta Accreta

Summary: the goal of this observational study is to evaluate the diagnostic ability of the main criteria currently adopted for the diagnosis of placenta accreta and to define the maternal outcomes in terms of complications of the different management strategies currently adoptable when placental accretism is suspected.

currently, the management of cases of placental accretism/percretism is not standardized. this study could help in assessing maternal and fetal outcomes related to the different therapeutic strategies applied in the clinical cases under study so that their management can be standardized in the near future. this is a retrospective and prospective, national multicenter study. patients will be treated according to clinical practice. the main instrumental findings of cases of suspected accretism will be collected and analyzed, and the progression of pregnancy and postpartum (by means of laboratory and instrumental tests) will be evaluated in order to define the outcomes of conservative management (cesarean section with placenta in situ) versus more radical management (cesarean section and concomitant hysterectomy). in particular, clinical trends (by means of assessment of vital parameters, laboratory tests, ultrasound images or instrumental examinations) in pregnancy, in the immediate postoperative period and during subsequent outpatient follow-up visits will be analyzed. in general, in the absence of complications, visits will be performed twice a week during pre-partum. postpartum follow-up is not standardized, as it will depend strictly on the procedure performed and the occurrence or absence of complications. there are no questionnaires and/or rating scales.

Eligibility criteria:
inclusion criteria: * age between 18 years and 44 years * pregnant women with suspected placental accretism * acquisition of informed consent form exclusion criteria: none

Keywords: diagnosis
an exploratory clinical study of apatinib for the 2nd treatment of esophageal cancer or esophageal and gastric

Conditions: Esophagus Cancer, Stage III; Esophageal Gastric Cardia Type Metaplasia; Esophagus Cancer, Stage IV

Summary: the purpose of this phase ii, open-label, single arm, exploratory study is to evaluate the efficacy and the safety of apatinib（500mg/d）for the second - line treatment of esophageal cancer or esophageal and gastric

this study is a prospective,single-center,single arm,ⅱ exploratory study.to explore the clinical study of the efficacy and safety of the treatment of vegfr-2 high expression by apatinib mesilate.the main research object for first-line treatment failure ⅲ/ⅳ integration of a period of esophageal or gastric esophagus cancer patients.the main purpose of the study was to evaluate apatinib for the median pfs of the esophageal and esophageal gastric junction carcinoma of the esophagus with high expression of vegfr-2. the objective of secondary research is to evaluate the safety of apatinib for second-line treatment of esophageal and esophageal gastric junction cancer objective response rate (cr + pr) and median os and explore the relationship between vegfr-2 high expression and apatinib efficacy and related prognostic factors. thirty patients were enrolled in the study group. the group was expected to be enrolled in the group for 24 months, followed by 6 months of follow-up and 6 months of data statistics. the drug regimen was a single drug apatinib 500mg qd po.please refer to the crf table for details.

Eligibility criteria:
inclusion criteria: * ≥ 18 and ≤ 75 years of age * have failed for 1 lines of chemotherapy * ecog performance scale 0 - 2. * adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 90g/l, platelets ≥ 80×10\^9/l, neutrophils ≥ 1.5×10\^9/l, total bilirubin within 1.25×the upper limit of normal(uln), and serum transaminase≤2.5×the uln (if liver metastases, serum transaminase≤5×the uln), serum creatine ≤ 1.5 x uln, creatinine clearance rate ≥ 50ml/min. * life expectancy of more than 12 months exclusion criteria: * existing therapy related toxicity of prior chemotherapy and/or radiation therapy * intercurrence with one of the following: hypertension, coronary artery disease, arrhythmia and heart failure * any factors that influence the usage of oral administration * the center of the tumor invaded local large blood vessels * within 4 weeks before the first use of drugs, occurs pulmonary hemorrhage (≥ ctcae class 2) or other parts' hemorrhage (≥ ctcae class 3). * within 6 months before the first treatment occurs artery / venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism, etc. * less than 4 weeks from the last clinical trial
the effect of pullsed magnetic field induction on improving the forearm tissue muscle performance

Conditions: Medical Oncology

Summary: pulsed electromagnetic field therapy (pemft) is a reparative technique most commonly used in the field of orthopedics for the treatment of non-union fractures. the aim is to test the effect of the magnetic induction on brute force of treated muscle in oncological patients. oncology patients were chosen as we assume that the ipmrovement will be more noticable in oncology patients than in a non-oncology, healthy subjects.


Eligibility criteria:
inclusion criteria: * patiant from the oncology clinic exclusion criteria: * known bone disease * pregnancy * birth defects or acquired uper extremity * neurology disease * medical history in the forehand * pacemaker neural modulation pacer.
vibrotactile foot device for freezing of gait in parkinson's disease

Conditions: Parkinson Disease; Freezing of Gait

Summary: freezing of gait (fog) is a common, disabling symptom of later stage parkinson's disease (pd), and can induce significant morbidity and mortality by increasing risk of falls as the disease progresses. despite optimum medical management and deep brain stimulation therapy, many patients with pd are incapacitated by fog and gait disorders. non-invasive vibrotactile stimulation has been reported to potentially improve fog of patients with pd. however, results of studies were variable, and there is a lack of convenient vibrotactile devices ready for daily use with reliable clinical trial data. in the proposed study, the investigator will test the effect of a newly developed vibrotactile foot device (smart shoe) on participants diagnosed with pd and fog. eeg and fmri are obtained in order to investigate the underlying neurological mechanism.


Eligibility criteria:
inclusion criteria: * age 30-80 years * diagnosed with parkinson's disease according to mds clinical diagnostic criteria * stable drug therapy without any change in the past one month * subjective presence of fog more than once per day * objective presence of fog by provoking tasks, e.g., gait initiation, rapid full turn, et al. * able to walk unaided at least 20 meters * provide written informed consent exclusion criteria: * stroke and other diseases interfering ambulation * severe foot sensory impairments disabling the individual to perceive vibratory stimulation * history of deep brain stimulation surgery
a continuation study to assess the effect of cellcept in patients with myasthenia gravis.

Conditions: Myasthenia Gravis Generalised

Summary: this 2 arm study will provide optional continuation of double-blind treatment with cellcept or placebo, in patients with myasthenia gravis who have achieved good symptom control in study wx17798. patients who have completed 36 weeks of treatment in study wx17798, with stable prednisone dosing for the last 4 weeks, can continue on blinded treatment with cellcept (1g bid) or placebo until the database for wx17798 is locked and unblinded. the anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * subjects who have completed 36 weeks of treatment in study wx17798, and who have demonstrated good symptom control with a stable prednisone dose for the final 4 weeks of that study. exclusion criteria: * regularly scheduled plasma exchange or intravenous immunoglobulin treatment; * medical condition, adverse event or intolerance of double-blind treatment which would preclude continuation.
tolerability and safety of immune globulin subcutaneous solution (igsc) and rhuph20 in pid

Conditions: Primary Immunodeficiency Diseases (PID)

Summary: the original purpose of the study is to assess the long-term safety, tolerability, and practicability of the subcutaneous (sc) treatment with immune globulin subcutaneous solution (igsc), 10% facilitated with recombinant human hyaluronidase (rhuph20) in participants with primary immunodeficiency diseases (pid) who have completed baxter clinical study protocol no. 160603. following a discussion with the fda, all participants still active in the study stopped treatment with rhuph20 to assure safety of the participants participating in the study and went into a safety follow-up. during this safety follow-up period, participants underwent either intravenous (iv) or sc treatment with igsc, 10%. the iv or sc administration route was at the discretion of the participant and the investigator.

igsc, 10% is the same product as immune globulin intravenous (human), 10% (igiv, 10%) quoted in study 160603. igsc, 10% is abbreviated to igi, 10% \[immune globulin infusion (human), 10%\] in the us the product is licensed (trade name gammagard liquid) for the intravenous (iv) and sc replacement therapy of antibody deficiency in patients with pid. in the eu this product is licensed (trade name kiovig) igsc, 10% with rhuph20 established name is innume glubulin infusion 10% (human) with recombinant human hyualuronidase. us trade name is hyqvia eu trade name is hyqvia

Eligibility criteria:
inclusion criteria: * participant has completed or is about to complete baxter clinical study protocol no. 160603. participants who have discontinued rhuph20 and reverted to intravenous or subcutaneous treatment due to an anti-rhuph20 antibody also may enroll for long-term safety monitoring. * participant/caretaker has reviewed, signed and dated informed consent * participant is willing and able to comply with the requirements of the protocol exclusion criteria: * participant has a serious medical condition such that the participant's safety or medical care would be impacted by participation in study 160902 * participant is scheduled to participate in another non-baxter clinical study involving an investigational product or investigational device during the course of this study * if female of childbearing potential, participant is pregnant or has a negative pregnancy test and does not agree to employ adequate birth control measures for the duration of the study
operative versus non-operative management of subacromial impingement

Conditions: Subacromial Impingement Syndrome

Summary: the study aims at determining the effectiveness and cost-effectiveness of surgical management of subacromial impingement (including partial tears) compared to conservative treatment. the research setting is prospective, randomised, and controlled. the aim of the study is to search out evidence based data of indications for subacromial decompression. the investigators also aim at offering patients the most efficient and effective treatment and reduce the number of operations that do not have sufficient effectiveness. the data obtained will facilitate developing guidelines for referrals to a specialist when subacromial impingement is suspected. the investigators hypothesise that there are subgroups of patients suffering from subacromial impingement that benefit from surgery whereas other subgroups are best treated conservatively.

subgroup analysis: * age * sex * duration of symptoms * presence of trauma before symptoms * presence of partial tear * degenerative findings * other findings in mri or arthroscopy * type of operation * co-morbidities * occupation * pain (vas) * objective shoulder function * activities of daily living

Eligibility criteria:
inclusion criteria: * age over 35 years old * duration of symptoms at least three months despite non-operative treatment * accepts both treatment options (operative and physical therapy) * must have pain in abduction of the shoulder * must have painful arc * must have pain in two of the three isometric tests (0 and 30 degrees of abduction, or external rotation) * a positive result in the impingement test (a subacromial injection of lidocaine reduces pain) exclusion criteria: * previous shoulder operations * too high risk for operation * any disease or social problem reducing the ability to co-operate * rheumatoid arthritis * severe arthrosis of the glenohumeral or acromioclavicular joint * a full-thickness rotator cuff tear in mri arthrography * a progressive malign disease * adhesive capsulitis * high-energy trauma before symptoms * cervical syndrome * shoulder instability

Keywords: subacromial impingement shoulder rct effectiveness cost-effectiveness
effect of mindful eating on body mass index in obese adolescents

Conditions: Adolescent Obesity

Summary: this study is designed to study the effect of a family based mindfulness training program with special focus on diet and nutrition on weight and cardiovascular risk markers in obese adolescents.

40 obese adolescents would be randomized into either a mindfulness based behavioral modification program or standard dietary counseling. at least one parent would be expected to attend the counseling sessions. patients would be followed for a period of 6 months. anthropometric parameters, questionaiires relating to quality of life and blood tests would be drawn at baseline and and at 6 months.

Eligibility criteria:
inclusion criteria * bmi at or greater than the 95th percentile for age and gender exclusion criteria

Keywords: obesity adolescence mindful eating
tbtc study 23c: pharmacokinetics of intermittent rifabutin and isoniazid with daily efavirenz

Conditions: HIV Infections; Tuberculosis

Summary: the aim of this trial is to study the efavirenz-rifabutin interaction. thus, this trial will enroll patients with hiv and tuberculosis co-infections who are receiving a rifabutin-based regimen and who plan to begin an antiretroviral regimen containing efavirenz dosed at 600 mg daily. enrollment in tb trials consortium study 23 is not a requirement for participation in this study. primary objective: to compare the pharmacokinetics of rifabutin at 600 mg twice a week in combination with efavirenz 600 mg daily to the pharmacokinetics of rifabutin 300 mg twice a week without efavirenz.


Eligibility criteria:
* patients with hiv and tuberculosis co-infections who are receiving a rifabutin-based regimen and who plan to begin an antiretroviral regimen containing efavirenz dosed at 600 mg daily.

Keywords: tuberculosis tb
is there any correlation among neonates anthropometry and neuromotor behaviour

Conditions: Cerebral Palsy, Autism or Other Neuromotor Behavior Abnormalities Correlation With Anthropometry

Summary: to explore the association among anthropometric parameters and neuromotor behaviour in neonates for early identification and prediction of later neuromotor deficit.

the association between anthropometric (birth weight, length and occipitofrontal circumference) measurement and hands-on measurement of above mentioned anthropometric dimensions and demographic dimension (bilateral forearm, midarm, calf and thigh) with neuromotor behaviour were explored.

Eligibility criteria:
inclusion criteria: * neonates born between ≥28 weeks and ≤ 42 weeks of gestation * birth weight between 1500 and 3000 grams * neonates are born under all the classifications of fenton growth charts (sga, aga and lga) * stable hemodynamics * free from infection * stable vitals exclusion criteria: * dermal conditions * chromosomal abnormalities * history of surgery * neural tube defect * cardiac abnormally

Keywords: correlation; infants; muscles; weight; length